Cytori’s Cardiac Celution: Encouraging Interim Data
In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction and chronic myocardial ischemia.
New Approval, Clinical Trial for YM Biosciences’ Cancer Drug
The company announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC).
Nasdaq Buoyed by Biotech
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
Potential Breakthrough in Search for AIDS Vaccine
Scientists at the Scripps Research Institute have isolated two antibodies that can prevent patients with HIV from developing severe AIDS.
Heart Failure Society of America Holds Annual Meeting
A roundup of news from the Heart Failure Society of America’s annual meeting.
Seaside Therapeutics Secures $30M to Fight Autism
Seaside Therapeutics has secured $30 million in funding from a private, unnamed family investment firm committed to finding treatments for autism and Fragile X syndrome.
Xenoport Reports Positive Data for Chronic Pain Drug
Most people wouldn’t think that a case of chicken pox could cause chronic pain, but many people across the U.S. feel the effects of this common childhood disease years after the red spots have disappeared.
First Swine Flu Vaccines Approved
The U.S. government has approved swine flu vaccines from four pharmaceutical companies, Reuters reports.
[Company Profile] Urovalve
Men with acute or chronic urinary retention find that the condition limits their normal activities, causes embarrassment, and poses serious health risks. Urovalve of Newark, NJ, seeks to replace catheterization with an updated treatment that returns bladder control to the patient.